Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
Ayala Pharmaceuticals (ADXS) is a clinical-stage biotech company pioneering novel cancer immunotherapies and small molecule treatments targeting rare tumors and aggressive cancers. This dedicated news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Our curated collection features official press releases, trial result announcements, and expert analyses of ADXS's proprietary bacterial-based immunotherapy platform. Key focus areas include advancements in modifying the tumor microenvironment, progress across the company's oncology pipeline, and collaborations advancing next-generation cancer therapies.
Users can expect comprehensive coverage of:
• Clinical trial updates for immunotherapy candidates
• Strategic partnership announcements with biopharma leaders
• Regulatory developments across global markets
• Scientific presentations at major oncology conferences
Bookmark this page for verified updates on Ayala Pharm's progress in developing treatments that harness the immune system to combat challenging cancers. Check regularly for new insights into their dual-platform approach combining bacterial vectors and targeted small molecules.
Advaxis, Inc. (OTCQX: ADXS) reported progress in its Phase 1 clinical study for ADXS-504, targeting biochemically recurrent prostate cancer. Enrollment at the second dose level is expanding following completion of dose escalation, with the drug exhibiting good tolerability and no serious adverse events reported. Four of six patients are still participants, and immune response data is being collected. ADXS-504 aims to generate T cell responses against multiple tumor antigens, potentially improving tumor control. The trial at Columbia University is designed to enhance understanding of safety and efficacy.
Ayala Pharmaceuticals and Advaxis have announced a definitive merger agreement, creating a combined company focusing on oncology therapeutics. Ayala stockholders will own approximately 62.5% of the new entity, while Advaxis stockholders will hold about 37.5%. The merger aims to advance Ayala’s AL102, under Phase 2/3 RINGSIDE study for desmoid tumors, alongside Advaxis’s ADXS-504 for prostate cancer. The combined company intends to pursue a Nasdaq listing and expects to leverage added cash and infrastructure to enhance its clinical portfolio.
Advaxis announces the completion of the first dose level and the initiation of enrollment for the second dose level in the ADXS-504 study for biochemically recurrent prostate cancer. Preliminary results indicate that ADXS-504 monotherapy is safe and well-tolerated. The company plans to present clinical data and PSA values at an upcoming medical conference. Financially, Advaxis reported R&D expenses of $2.2 million, up from $1.7 million YoY, while G&A expenses decreased to $2.1 million from $2.7 million. The company maintains a cash runway into Q3 2024.
Advaxis has reported progress on its Phase 1 study of ADXS-504, an off-the-shelf neoantigen therapy for biochemically recurrent prostate cancer. The study has completed safety evaluations of the first dose level and is moving to the second dose level. Initial results indicate ADXS-504 is safe and well-tolerated, with mild side effects. The therapy aims to generate T cell responses against 24 tumor antigens, potentially enhancing tumor control. Data from both dose levels will be presented at an upcoming medical conference.
Advaxis, a clinical-stage biotechnology company, announced its Q2 financial results for the period ending April 30, 2022, alongside significant clinical updates. The company reported a notable reduction in R&D expenses, totaling $1.5 million, down from $4.3 million year-over-year, due to discontinued studies. Advaxis highlighted encouraging clinical data for ADXS-503 in combination with KEYTRUDA at the 2022 ASCO Annual Meeting, showing a 67% disease control rate in a first-line setting. Additionally, a 1-for-80 reverse stock split was executed to aid NASDAQ listing efforts.
Advaxis, Inc. (OTCQX: ADXS) announced a one-for-80 reverse stock split effective June 6, 2022. This decision follows the approval by stockholders on March 31, 2022, to implement a reverse split within a specified range. The split aims to enhance the company's position for strategic initiatives and facilitate approval for listing on The Nasdaq Capital Market. Each 80 shares will convert to one share, and adjustments will be made to stock options and warrants. Fractional shares will be cashed out based on the stock's closing price on the split date.
Advaxis, Inc. (OTCQX: ADXS) announced updated results from its ADXS-503 clinical trial, showing a 14% overall response rate (ORR) and a 36% disease control rate (DCR) among patients who previously progressed on KEYTRUDA®. In the first-line setting (Part C), DCR reached 67%. The trial assesses safety, tolerability, and immune responses in combination with KEYTRUDA® for metastatic NSCLC. Notably, durable clinical benefits were linked to immune activation involving NK cells and T-cells. Enrollment for further evaluation continues, aiming for an ORR of ≥20% in patients failing KEYTRUDA®.
Advaxis, Inc. (OTCQX: ADXS) announced its participation in the ASCO Annual Meeting, scheduled for June 3-7, 2022. The company will present data from two studies: a Phase 2 study of ADXS-503 in combination with pembrolizumab for metastatic non-small cell lung cancer and a Phase 1 study of ADXS-504 for biochemically recurrent prostate cancer. Key presentations include:
- Abstract #9038: ADXS-503 in NSCLC on June 6, 2022, 8-11 AM CDT.
- Abstract #9042: Immunogenicity in NSCLC on June 6, 2022, 8-11 AM CDT.
- Abstract #TPS5115: ADXS-504 on June 6, 2022, 1:15-4:15 PM CDT.
Advaxis, Inc. (ADXS) announced promising results from the KEYNOTE-46 Phase 1/2 trial, which evaluated ADXS-PSA combined with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC). Patients receiving the combination therapy showed a median overall survival (OS) of 33.7 months compared to 7.8 months with ADXS-PSA alone. For those with visceral metastasis, the OS was notably improved to 16.4 months. The study demonstrated that the therapy is safe, with manageable side effects. Advaxis continues to explore further development of Listeria monocytogenes-based immunotherapies.
Advaxis, Inc. (OTCQX: ADXS) announced its financial results for Q1 2022 and provided updates on its Phase 1/2 trial of ADXS-503 in NSCLC. The study yielded a 15.4% overall response rate and a 46% disease control rate with durable benefits. The company reported reduced R&D expenses of $1.7 million versus $2.6 million in Q1 2021 and decreased G&A expenses of $2.5 million from $3.0 million year-over-year. Advaxis also announced a $5 million convertible redeemable preferred stock offering. As of January 31, 2022, cash and equivalents stood at $36.5 million.
